Unmet needs in the diagnosis and treatment of Parkinson's disease psychosis and dementia-related psychosis.


Journal

International journal of psychiatry in clinical practice
ISSN: 1471-1788
Titre abrégé: Int J Psychiatry Clin Pract
Pays: England
ID NLM: 9709509

Informations de publication

Date de publication:
Mar 2023
Historique:
medline: 15 5 2023
pubmed: 17 5 2022
entrez: 16 5 2022
Statut: ppublish

Résumé

Dementia due to Parkinson's disease and Alzheimer's disease are associated with behavioural and psychological symptoms, including psychosis. Long-term management presents a challenge for health care providers and caregivers. Symptoms of psychosis include hallucinations and delusions; if untreated, these can lead to institutionalisation, decreased quality of life, and significant patient and caregiver distress. A critical step in the effective management of dementia-related psychosis (DRP) is the identification and diagnosis of affected patients. The lack of a standardised diagnostic approach presents a barrier to treatment and there are no consensus guidelines for DRP. Furthermore, there are no approved therapies for the treatment of DRP. Antipsychotic medications are often prescribed off-label, even though some are associated with an increased risk of adverse events or mortality. We present currently available screening tools and guidelines for the diagnosis and treatment of Parkinson's disease psychosis and DRP in the context of what is needed for effective management of psychosis.KEY POINTSWe present currently available screening tools and guidelines for Parkinson's disease psychosis and dementia-related psychosis, and discuss the unmet need for simple clinical diagnostic tools and treatment guidelines.The identification of psychosis is variable across different settings and specialties, without a unified approach to screening, definition, or diagnosis.Currently used tools for defining and assessing psychosis in a research setting are usually too cumbersome for everyday clinical practice.The development of a standardised set of diagnostic criteria would provide clinicians the opportunity to improve the detection, treatment, and quality of life of patients and their caregivers.

Identifiants

pubmed: 35574992
doi: 10.1080/13651501.2022.2058406
doi:

Substances chimiques

Piperidines 0
Urea 8W8T17847W
Antipsychotic Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

69-81

Auteurs

Marwan Sabbagh (M)

Dignity Health/St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA.

Gary W Small (GW)

Department of Psychiatry, Hackensack University Medical Center, Behavioral Health Service, Hackensack Meridian Health, Hackensack, NJ, USA.

Stuart H Isaacson (SH)

Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, FL, USA.

Yasar Torres-Yaghi (Y)

Department of Neurology, National Parkinson's Foundation Center for Excellence, Translational Neurotherapeutics Program, Movement Disorders Program, MedStar Georgetown Hospital, Washington, DC, USA.

Fernando Pagan (F)

Department of Neurology, National Parkinson's Foundation Center for Excellence, Translational Neurotherapeutics Program, Movement Disorders Program, MedStar Georgetown Hospital, Washington, DC, USA.

Rajesh Pahwa (R)

Department of Neurology, University of Kansas Medical Center, Kansas City, KS, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH